Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 9/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29720427 | 1.00 | TLR8 (1.00) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL1232530 | 0.92 | TLR7 (0.85) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL1234050 | 0.86 | TLR7 (0.75) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL22806917 | 0.84 | TLR8 (0.72) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL29787346 | 0.84 | TLR8 (0.72) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL1233657 | 0.83 | TLR7 (0.71) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL1233446 | 0.83 | TLR7 (0.70) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL3999205 | 0.82 | TLR8 (0.70) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL3991826 | 0.82 | TLR8 (0.70) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL5572423 | 0.81 | TLR8 (0.68) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259202-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-114746420-A | 1- (4- (aminomethyl) benzyl) -2-butyl-2H-pyrazolo [3,4-c ] quinolin-4-amine derivatives as Toll-like receptor (TLR)7/8 agonists and related compounds and antibody drug conjugates thereof for cancer therapy and diagnosis | 苏特罗生物制药公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114585382-A | Kink-immunostimulatory conjugates and related compositions and methods | 小利兰·斯坦福大学理事会 | 2022-06-03 | — | — | CN | disclosed |
| EP-3983410-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | Sutro Biopharma, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020257235-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257235-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-9145410-B2 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2012-05-17 | — | — | US | disclosed |
| US-7879849-B2 | such as 1-(2-Methylpropyl)-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine, used as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-7544697-B2 | Pyrazolopyridines and analogs thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | IL4, IL4I1, IL2 | TLR8 457/4885TLR7 265/4885ADORA3 511/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | TLR8 319/4885TLR7 179/4885ADORA3 610/4885 |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL4I1, IL2 | TLR8 457/4885TLR7 265/4885ADORA3 511/4885 |
| US-20220259202-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | TLR1, TLR4, TLR7 | TLR8 4/4885TLR7 3/4885ADORA3 523/4885 |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL2, IL4I1 | TLR8 319/4885TLR7 179/4885ADORA3 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.